论文检索

FLEX-CP-DT：计数终点与时间趋势下的期中无效性分析AI 解读

Many large-scale phase III trials with recurrent event endpoints include a pre-planned interim analysis to evaluate early futility. Conditional power (CP), which quantifies the probability of achieving statistical significance at the final analysis given the interim data, is a commonly used tool to support such decisions. The standard negative binomial model with an offset term, widely adopted for analyzing recurrent events, implicitly assumes that event rates and treatment…

含潜在变点的生存时间与纵向肿瘤负荷治愈率联合模型AI 解读

In non-small cell lung cancer (NSCLC) clinical trials, tumor burden (TB) is a key longitudinal biomarker for assessing treatment effects. Typically, standard-of-care (SOC) therapies and some novel interventions initially decrease TB; however, many patients subsequently experience an increase-indicating disease progression-while others show a continuous decline. In patients with an eventual TB increase, the change point marks the onset of progression and must occur before the…

结合肿瘤负荷与生存结局评价肿瘤试验处理效应AI 解读

In early-phase cancer clinical trials, the limited availability of data presents significant challenges in developing a framework to efficiently quantify treatment effectiveness. To address this, we propose a novel utility-based Bayesian approach for assessing treatment effects in these trials, where data scarcity is a major concern. Our approach synthesizes tumor burden, a key biomarker for evaluating patient response to oncology treatments, and survival outcome, a widely…